Hearing loss is the third most prevalent disorder in humans above even diabetes and cancer. According to the CDC around 15% of adults over the age of 18 have some degree of hearing loss. Much of the damage occurs acutely or progressively through exposure to noise and ototoxic substances, but a common component of this damage is through oxidative damage via reactive oxygen species. We have developed a gene therapy that is neuroprotective against the oxidative damage that leads to inner and outer hair cell death in the inner ear. Ongoing research will use this GT to produce proof of principle data sets demonstrating efficacy and safety of the therapy.
to view more information about this project.